![Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41574-020-0399-8/MediaObjects/41574_2020_399_Fig1_HTML.png)
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology
![Frontiers | Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes Frontiers | Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes](https://www.frontiersin.org/files/Articles/440649/fendo-10-00080-HTML-r1/image_m/fendo-10-00080-g001.jpg)
Frontiers | Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
![Mechanism of action for GIP, GLP-1 analogues and DPP4 inhibitors in... | Download Scientific Diagram Mechanism of action for GIP, GLP-1 analogues and DPP4 inhibitors in... | Download Scientific Diagram](https://www.researchgate.net/publication/260680847/figure/fig3/AS:513088665001985@1499341278619/Fig-3-Mechanism-of-action-for-GIP-GLP-1-analogues-and-DPP4-inhibitors-in-controlling.png)
Mechanism of action for GIP, GLP-1 analogues and DPP4 inhibitors in... | Download Scientific Diagram
![Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications - ScienceDirect Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2213177918300416-fx1.jpg)
Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications - ScienceDirect
![DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment | Hypertension DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment | Hypertension](https://www.ahajournals.org/cms/asset/fbfe42bc-63ea-4c7e-8cc7-141b01aa6920/hypertensionaha.121.18348.fig04.jpg)
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment | Hypertension
![Direct head‐to‐head comparison of glycaemic durability of dipeptidyl peptidase‐4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta‐analysis of long‐term randomized controlled trials - Chen - 2018 - Diabetes, Direct head‐to‐head comparison of glycaemic durability of dipeptidyl peptidase‐4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta‐analysis of long‐term randomized controlled trials - Chen - 2018 - Diabetes,](https://dom-pubs.onlinelibrary.wiley.com/cms/asset/1612e8f2-b515-4edc-bc9e-90403794bb63/dom13147-fig-0001-m.jpg)